Beyond gastric emptying: a "toxic" lesson about gastroparesis.
The first published controlled trial of intrapyloric botulinum toxin for gastroparesis failed to demonstrate a significant effect of treatment on symptoms, despite an improvement in gastric emptying. In this editorial, I discuss the limitations and implications of this study, with particular emphasis on what the use of botulinum toxin can teach us about the pathophysiology of gastroparesis and other gastrointestinal smooth muscle disorders.
Pasricha
Pankaj J
PJ
D019274:Botulinum Toxins, Type A / Q000494:pharmacology* / Q000627:therapeutic use*; D005746:Gastric Emptying / Q000187:drug effects*; D018589:Gastroparesis / Q000188:drug therapy*; D006801:Humans; D009465:Neuromuscular Agents / Q000494:pharmacology* / Q000627:therapeutic use*
D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A